|Tested species reactivity||Bovine, Dog, Chicken, Horse, Guinea pig, Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide between amino acids 150-250 of the internal region of human VEGFA protein sequence.|
|Purification||Antigen affinity chromatography|
|Storage buffer||tris citrate/tris phosphate, pH 7-8|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Western Blot (WB)||1 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
In Western blot, a band is seen at ~42 kDa with a chimera transfected lysate representing the homodimer VEGFA.
Another faint band is seen at ~21 kDa, representing the monodomer form of VEGFA.
This antibody is not recommended for IHC applications.Suggested positive control: antigen standard for VEGFA (transient overexpression lysate).
VEGFA is a member of the PDGF/VEGF growth factor family and is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome.
VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, are thought to be important for the development of embryonic vasculature. It has been shown that an alternately spliced form of FLT1 produces a soluble protein, termed sFLT1, which binds vascular endothelial growth factor with high affinity, playing an inhibitory role in angiogenesis.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.